London Co. of Virginia lessened its position in shares of Bruker Corporation (NASDAQ:BRKR – Free Report) by 7.2% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 2,584,029 shares of the medical research company’s stock after selling 199,096 shares during the quarter. London Co. of Virginia’s holdings in Bruker were worth $93,336,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other large investors have also modified their holdings of the company. Los Angeles Capital Management LLC acquired a new stake in Bruker during the fourth quarter worth $26,000. Allworth Financial LP lifted its holdings in shares of Bruker by 40.6% during the 3rd quarter. Allworth Financial LP now owns 890 shares of the medical research company’s stock worth $29,000 after acquiring an additional 257 shares during the period. Parallel Advisors LLC lifted its holdings in shares of Bruker by 121.0% during the 4th quarter. Parallel Advisors LLC now owns 875 shares of the medical research company’s stock worth $41,000 after acquiring an additional 479 shares during the period. Summit Securities Group LLC acquired a new stake in shares of Bruker during the 4th quarter valued at about $50,000. Finally, Covestor Ltd boosted its position in shares of Bruker by 304.6% during the 4th quarter. Covestor Ltd now owns 1,416 shares of the medical research company’s stock valued at $67,000 after acquiring an additional 1,066 shares in the last quarter. 79.52% of the stock is currently owned by institutional investors and hedge funds.
Analysts Set New Price Targets
A number of analysts recently weighed in on BRKR shares. TD Cowen reissued a “hold” rating on shares of Bruker in a research note on Wednesday, July 15th. Stifel Nicolaus set a $45.00 price target on shares of Bruker in a research note on Friday, May 8th. Wall Street Zen raised Bruker from a “hold” rating to a “buy” rating in a report on Saturday, May 9th. UBS Group set a $60.00 price objective on Bruker in a research note on Wednesday, June 24th. Finally, Leerink Partners increased their target price on Bruker from $60.00 to $70.00 and gave the stock an “outperform” rating in a report on Tuesday, July 7th. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, six have assigned a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $56.79.
Bruker Trading Down 2.7%
Shares of Bruker stock opened at $60.45 on Friday. The stock has a market capitalization of $9.20 billion, a P/E ratio of -251.88, a price-to-earnings-growth ratio of 1.94 and a beta of 1.29. The company has a quick ratio of 0.72, a current ratio of 1.55 and a debt-to-equity ratio of 0.67. The company has a 50-day simple moving average of $56.32 and a 200 day simple moving average of $46.32. Bruker Corporation has a 12-month low of $28.53 and a 12-month high of $64.54.
Bruker (NASDAQ:BRKR – Get Free Report) last released its quarterly earnings results on Wednesday, May 6th. The medical research company reported $0.31 EPS for the quarter, beating analysts’ consensus estimates of $0.23 by $0.08. The firm had revenue of $823.40 million for the quarter, compared to analyst estimates of $795.62 million. Bruker had a negative net margin of 0.65% and a positive return on equity of 11.60%. The company’s revenue for the quarter was up 2.7% compared to the same quarter last year. During the same period in the previous year, the business earned $0.47 earnings per share. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. Research analysts expect that Bruker Corporation will post 2.12 earnings per share for the current fiscal year.
Bruker Dividend Announcement
The company also recently announced a quarterly dividend, which was paid on Tuesday, July 7th. Stockholders of record on Monday, June 22nd were paid a $0.05 dividend. The ex-dividend date was Monday, June 22nd. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.3%. Bruker’s payout ratio is -83.33%.
Bruker Company Profile
Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.
Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.
In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.
Featured Stories
- Five stocks we like better than Bruker
- Telecom Earnings Reveal a Sector That Finally Looks Healthier
- Defense Earnings Show Readiness Now and Modernization Ahead
- Why Palantir Investors Aren’t Panicking While the Rest of AI Sells Off
- MarketBeat Week in Review – 07/20- 07/24
Want to see what other hedge funds are holding BRKR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bruker Corporation (NASDAQ:BRKR – Free Report).
Receive News & Ratings for Bruker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker and related companies with MarketBeat.com's FREE daily email newsletter.
